Applicant: Hiroyuki Tsunoda et al. Attorney's Docket No.: 14875-0153US1 / C1-A0320Y2P-US

Serial No.: 10/551,504

Filed: September 29, 2005

Page : 2 of 19

Amendments to the Specification:

Please delete the previous abstract at page 91 of the application as filed and add the following <u>new</u> abstract:

Anti-human Mpl antibodies were isolated and purified. Anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were prepared using genetic engineering techniques and anti-human Mpl sc(Fv)2 was also humanized. The diabodies and sc(Fv)2 were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.